The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers
Open accessAbstract
Tumor markers are playing an increasingly important role in cancer detection and management. These laboratory-based tests are potentially useful in screening for early malignancy, aiding cancer diagnosis, determining prognosis, surveillance following curative surgery for cancer, up front predicting drug response or resistance, and monitoring therapy in advanced disease. Clinically useful markers include fecal occult blood testing in screening for early colorectal cancer, carcinoembryonic antigen in the management of patients with colorectal cancer, both α-fetoprotein and human chorionic gonadotrophin in the management of patients with non-seminomatous germ cell tumors, CA 125 for monitoring therapy in patients with ovarian cancer, estrogen receptors for predicting response to hormone therapy in breast cancer, human epidermal growth factor receptor 2 for the identification of women with breast cancer likely to respond to trastuzumab (Herceptin) and KRAS mutational status for identifying patients with advanced colorectal cancer likely to benefit from treatment with the anti-epidermal growth factor receptor antibodies, cetuximab and panitumumab. Although widely used, the value of prostate-specific antigen screening in reducing mortality from prostate cancer is unclear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Buys, S. S. (2011) · JAMA · doi:10.1001/jama.2011.766 · Cited by 1,323
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Self-citationCookson, M. S., Aus, G., Burnett, A. L., Canby-Hagino, E. D., D’Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., Goldenberg, S. L., Hernandez, J., et al. (2007) · Journal of Urology · doi:10.1016/j.juro.2006.10.097 · Cited by 844
Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70026-9 · Cited by 829
Screening for colorectal cancer using the faecal occult blood test, Hemoccult
Hewitson, P., Glasziou, P. P., Irwig, L., Towler, B., & Watson, E. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001216.pub2 · Cited by 742
Renehan, A. G., Egger, M., Saunders, M. P., & O'Dwyer, S. T. (2002) · BMJ · doi:10.1136/bmj.324.7341.813 · Cited by 651
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.2.116 · Cited by 596
Self-citationProstate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
Hernández, J., & Thompson, I. M. (2004) · Cancer · doi:10.1002/cncr.20480 · Cited by 527
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., & Topolcan, O. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.021 · Cited by 506
Self-citationJanicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C. G. J. F., Selbmann, H.-K., Graeff, H., & Schmitt, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.12.913 · Cited by 434
Effect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer Patients
Earle, C. C., Schrag, D., Neville, B. A., Yabroff, K. R., Topor, M., Fahey, A., Trimble, E. L., Bodurka, D. C., Bristow, R. E., Carney, M., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj019 · Cited by 416
Follow-up of patients with curatively resected colorectal cancer: a practice guideline
Figueredo, A., Rumble, R. B., Maroun, J., Earle, C. C., Cummings, B., McLeod, R., Zuraw, L., Zwaal, C., & the members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care (2003) · BMC Cancer · doi:10.1186/1471-2407-3-26 · Cited by 392
Clinical utility of biochemical markers in colorectal cancer
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Klapdor, R., Lamerz, R., Nilsson, O., Sturgeon, C., & Topolcan, O. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00811-0 · Cited by 374
Self-citationCA 15-3: Uses and limitation as a biomarker for breast cancer
Duffy, M. J., Evoy, D., & McDermott, E. W. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.08.039 · Cited by 371
Self-citationBuys, S. S., Partridge, E., Greene, M. H., Prorok, P. C., Reding, D., Riley, T. L., Hartge, P., Fagerstrom, R. M., Ragard, L. R., Chia, D., et al. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.05.005 · Cited by 346
Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations
Molina, R., Barak, V., van Dalen, A., Duffy, M. J., Einarsson, R., Gion, M., Goike, H., Lamerz, R., Nap, M., Sölétormos, G., et al. (2005) · Tumor Biology · doi:10.1159/000089260 · Cited by 334
Self-citationCA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
DUFFY, M. J., BONFRER, J. M., KULPA, J., RUSTIN, G. J. S., SOLETORMOS, G., TORRE, G. C., TUXEN, M. K., & ZWIRNER, M. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00130.x · Cited by 317
Self-citationGilligan, T. D., Seidenfeld, J., Basch, E. M., Einhorn, L. H., Fancher, T., Smith, D. C., Stephenson, A. J., Vaughn, D. J., Cosby, R., & Hayes, D. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4481 · Cited by 297
Duffy, M. J. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1194 · Cited by 229
Self-citationSturgeon, C. M., Duffy, M. J., Hofmann, B. R., Lamerz, R., Fritsche, H. A., Gaarenstroom, K., Bonfrer, J., Ecke, T. H., Grossman, H. B., Hayes, P., et al. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.133124 · Cited by 211
Self-citationRole of tumor markers in patients with solid cancers: A critical review
Duffy, M. J. (2007) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2006.12.001 · Cited by 179
Self-citationPredictive Markers in Breast and Other Cancers: A Review
Duffy, M. J. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.046227 · Cited by 174
Self-citationKarsa, L., Patnick, J., & Segnan, N. (2012) · Endoscopy · doi:10.1055/s-0032-1309822 · Cited by 173
Clinical Uses of Tumor Markers: A Critical Review
Duffy, M. J. (2001) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/20014091084218 · Cited by 161
Self-citationPharmacogenetics and pharmacogenomics of anticancer agents
Huang, R. S., & Ratain, M. J. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20002 · Cited by 155
Use of molecular markers for predicting therapy response in cancer patients
Duffy, M. J., O’Donovan, N., & Crown, J. P. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.004 · Cited by 123
Self-citationDuffy, M. J., van Rossum, L. G. M., van Turenhout, S. T., Malminiemi, O., Sturgeon, C., Lamerz, R., Nicolini, A., Haglund, C. H., Holubec, L., Fraser, C. G., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25654 · Cited by 111
Self-citationFojo, T., & Parkinson, D. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1277 · Cited by 110
Use of Biomarkers in Screening for Cancer
Duffy, M. J. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7215-0_3 · Cited by 69
Self-citationSerum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
Tuxen, M. K., Sölétormos, G., & Dombernowsky, P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1787 · Cited by 68
Cited by
Nanoparticle-Based Immunochemical Biosensors and Assays: Recent Advances and Challenges
Farka, Z., Juřík, T., Kovář, D., Trnková, L., & Skládal, P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00037 · Cited by 694
Bodaghi, A., Fattahi, N., & Ramazani, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13323 · Cited by 336
RetractedGallaher, J. A., Enriquez-Navas, P. M., Luddy, K. A., Gatenby, R. A., & Anderson, A. R. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2649 · Cited by 268
Critical review and meta-analysis of biological variation estimates for tumor markers
Marques-Garcia, F., Boned, B., González-Lao, E., Braga, F., Carobene, A., Coskun, A., Díaz-Garzón, J., Fernández-Calle, P., Perich, M. C., Simon, M., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0725 · Cited by 24
Metadata
- Authors
- Duffy, M. J.
- Venue
- Medical Principles and Practice
- Publisher
- S. Karger AG
- Published
- 2012-05-15
- Volume
- 22
- Issue
- 1
- Pages
- 4-11
- ISSN
- 1011-7571 (ISSN-L)
- 1423-0151
- OpenAlex
- W2003487510
- Cited by
- 278
- References
- 37
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.